Beloc 40 mg Tripada Healthcare Pvt. Ltd.

£15.00

Beloc 40mg represents Tripada Healthcare’s metoprolol research formulation designed for cardiovascular receptor investigations. Premium laboratory compound for beta-adrenergic research protocols only.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Beloc 40 mg Tripada Healthcare Pvt. Ltd.
Beloc 40 mg Tripada Healthcare Pvt. Ltd.
£15.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Research Overview: Beloc

Beloc 40mg is a selective beta1-adrenergic receptor antagonist manufactured by Tripada Healthcare Pvt. Ltd. for advanced cardiovascular research applications. This metoprolol formulation enables researchers to investigate beta-blocker mechanisms in controlled laboratory environments. As a leading Stroid UK Shop, we provide pharmaceutical-grade compounds for academic and institutional studies examining adrenergic receptor modulation.

Laboratory Applications

Research scientists utilise Beloc 40mg to examine beta1-selective antagonism pathways in cardiovascular tissue models. This compound facilitates studies into heart rate regulation, blood pressure mechanisms, and myocardial contractility responses. Investigators exploring metoprolol research protocols can analyse dose-response relationships and receptor binding affinities. The formulation supports comparative studies alongside selective androgen receptor modulators and peptide compounds in multi-pathway research designs.

Product Specifications

Beloc 40mg Technical Data
Parameter Value
Active Compound Metoprolol
Dosage Strength 40mg
Manufacturer Tripada Healthcare Pvt. Ltd.
Product Code EU14172
CAS Number Verify with supplier
Storage Requirements Room temperature, dry conditions

Research Compliance

This product is manufactured exclusively for in-vitro research purposes and laboratory investigations. Beloc 40mg is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must possess appropriate qualifications and facilities for handling pharmaceutical research compounds. All studies should comply with institutional ethics guidelines and regulatory frameworks governing cardiovascular research protocols.

Related